<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621188</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-2003</org_study_id>
    <nct_id>NCT04621188</nct_id>
  </id_info>
  <brief_title>Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)</brief_title>
  <official_title>A Phase II Single-group Assignment, Multicenter Study of Efficacy and Safety of Lorlatinib Monotherapy After Failure of First-line Tyrosine Kinase Inhibitor in Patients With Advanced ROS1-positive Non-small Cell Lung Cancer (ALBATROS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular&#xD;
      subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer&#xD;
      sensitivity to the inhibitor crizotinib. Crizotinib, which is a tyrosine kinase inhibitor&#xD;
      (TKI), has been shown to be effective in tumors in several retrospective studies.&#xD;
&#xD;
      Recently the FDA approved entrectinib for the treatment of patients with ROS1-positive&#xD;
      metastatic NSCLC. This indication is based on the results of pooled data from several trials.&#xD;
      Together, these studies demonstrate the efficacy for entrectinib across a variety of solid&#xD;
      tumor types including NSCLC with ROS1 fusion.&#xD;
&#xD;
      However, despite the efficacy of crizotinib or entrectinib in ROS1-positive NSCLC, patients&#xD;
      will develop resistance to these tyrosine kinase inhibitors.&#xD;
&#xD;
      Lorlatinib is a new and potent ROS1 / ALK inhibitor optimized to penetrate the blood-brain&#xD;
      barrier. A recent study has investigated the activity of lorlatinib against the&#xD;
      crizotinib-resistant ROS1G2032R mutation. In this situation, lorlatinib effectively inhibited&#xD;
      the catalytic activity of recombinant ROS1G2032R resulting in an antiproliferative response.&#xD;
      Because of its potency as an ROS1 inhibitor and its ability to suppress the resistant ROS1&#xD;
      mutations, lorlatinib could be a treatment of choice in ROS1-positive NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) at 8 weeks by investigators</measure>
    <time_frame>8 weeks</time_frame>
    <description>ORR is defined as the percentage of subjects with a confirmed complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR) at 8 weeks by Independent Reviewer Committee (IRC)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of subjects with a confirmed at 16 weeks complete response (CR) or partial response (PR) as per RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time between the date of inclusion and the first date of documented disease progression (according to RECIST v1.1) or death (from any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the date of inclusion to the earliest date of disease progression (according to RECIST v1.1.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) at 8 weeks weeks)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Proportion of patients have achieved a confirmed best overall response of CR, PR or SD (Stable Disease) (according to RECIST v1.1.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) first documented response (CR or PR) to the earliest date of disease progression, or death due to any cause.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Time from the date of the first documented response (CR or PR) to the earliest date of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) months</measure>
    <time_frame>12 months and 24 months</time_frame>
    <description>Time from the date of first dose of study drug to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Nervous System (CNS) Objective response rate (C-ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>ORR estimated in patients with measurable CNS metastases at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CNS duration of response (C-DOR) measurable CNS metastases at baseline.</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>DOR estimated in patients with measurable CNS metastases at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CNS progression</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>In patients without brain metastases baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of EuroQol Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>At all scheduled time points</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Lorlatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lorlatinib</intervention_name>
    <description>100 mg once daily</description>
    <arm_group_label>Lorlatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Written Informed Consent: Subjects must have signed and dated an IRB/IEC&#xD;
             approved written informed consent form in accordance with regulatory and institutional&#xD;
             guidelines. This must be obtained before the performance of any protocol related&#xD;
             procedures that are not part of normal subject care. Subjects must be willing and able&#xD;
             to comply with scheduled visits, treatment schedule, and laboratory testing&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed diagnosis of locally advanced&#xD;
             not eligible to a local treatment or metastatic NSCLC (Stage IIIB, IIIC or IV&#xD;
             accordingly to 8th classification TNM, UICC 2015) that carries an ROS1 rearrangement,&#xD;
             as determined by the molecular biology platform of the investigator by FISH assay or&#xD;
             by Immunohistochemistry (IHC), or Next Generation Sequencing (NGS) or RNA sequencing&#xD;
             approach.&#xD;
&#xD;
          -  Disease Status Requirements: Disease progression meeting RECISTv1.1 after one prior&#xD;
             line of treatment with crizotinib or entrectinib (+ one line of chemotherapy with or&#xD;
             without immunotherapy before TKI treatment).&#xD;
&#xD;
          -  Tumor Requirements: All Patients must have at least one measurable target lesion&#xD;
             according to RECIST v1.1. In addition, patients with asymptomatic and neurologically&#xD;
             stable CNS metastases (including patients controlled with stable or decreasing steroid&#xD;
             use within the last week prior to study entry) will be eligible. The brain metastases&#xD;
             may be newly diagnosed after disease progression with crizotinib or entrectinib or be&#xD;
             present as progressive disease after surgery, whole brain radiotherapy or stereotactic&#xD;
             radiosurgery (see Exclusion Criterion for the lapsed time period required between the&#xD;
             end of radiotherapy and study entry). Patients who have leptomeningeal disease (LM) or&#xD;
             carcinomatous meningitis (CM) will be eligible if the LM/CM is visualized on MRI or if&#xD;
             documented baseline cerebral spinal fluid (CSF) positive cytology is available and&#xD;
             asymptomatic and neurologically stable (including patients controlled with stable or&#xD;
             decreasing steroid use within the last week prior to study entry).&#xD;
&#xD;
          -  Tumor Sample Requirement: Tumour biopsy sampling on fresh tissue (FFPE blocks&#xD;
             required) obtained after progression on crizotinib or entrectinib. Tumour biopsy&#xD;
             should be exploitable for molecular analysis. If the tumour biopsy is not exploitable,&#xD;
             the inclusion will be allowed if two blood samples are provided for tumoral cfDNA&#xD;
             analysis. The Sponsor will monitor a posteriori the exploitability of provided tumour&#xD;
             biopsies and will investigate the impossibility to perform or repeat tissue tumor&#xD;
             sampling.&#xD;
&#xD;
          -  Age ≥18 years.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks, in the opinion of the Investigator.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) ≤ 2&#xD;
&#xD;
          -  Adequate Bone Marrow Function, including: Absolute Neutrophil Count (ANC) ≥1.5 x&#xD;
             109/L; Platelets ≥100 x 109/L; Hemoglobin ≥9 g/dL.&#xD;
&#xD;
          -  Adequate Pancreatic Function, including: Serum lipase ≤1.5 x ULN.&#xD;
&#xD;
          -  Adequate Renal Function, including: Serum creatinine ≤1.5 x ULN or estimated&#xD;
             creatinine clearance ≥45 mL/min as calculated using the method standard for the&#xD;
             institution.&#xD;
&#xD;
          -  Adequate Liver Function, including: Total serum bilirubin ≤1.5 x ULN; Aspartate&#xD;
             Aminotransferase (AST) and Alanine Aminotransferase (ALT) ≤2.5 x ULN; ≤5.0 x ULN if&#xD;
             there is liver metastases involvement.&#xD;
&#xD;
          -  Participants must have recovered from treatment toxicities to CTCAE Grade ≤ 1 (for&#xD;
             participants who have developed interstitial lung disease [ILD], they must have fully&#xD;
             recovered) except for AEs that in the investigator' judgment do not constitute a&#xD;
             safety risk for the patient.&#xD;
&#xD;
          -  Participants must have recovered from effects of any major surgery, or significant&#xD;
             traumatic injury, at least 35 days before the first dose of lorlatinib&#xD;
&#xD;
          -  For all females of childbearing potential, a negative pregnancy test must be obtained&#xD;
             within the screening period. A patient is of childbearing potential if, in the opinion&#xD;
             of the investigator, she is biologically capable of having children and is sexually&#xD;
             active. Additionally, all females of childbearing potential must provide an agreement&#xD;
             to remain abstinent or use two adequate methods of contraception, including at least&#xD;
             one method with a failure rate of &lt; 1% per year, during the treatment period and for&#xD;
             at least 90 days after the last dose of study drug.&#xD;
&#xD;
          -  For men: agreement to remain abstinent or use an effective method of contraception&#xD;
             (e.g., condom) during the treatment period and for at least 14 weeks after the last&#xD;
             dose of study drug and agreement to refrain from donating sperm during this same&#xD;
             period.&#xD;
&#xD;
          -  Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the patient has been informed of all pertinent aspects of the study.&#xD;
&#xD;
          -  Willingness and ability to comply with the study scheduled visits, treatment plans,&#xD;
             laboratory tests and other procedure.&#xD;
&#xD;
          -  Participant has national health insurance coverage.&#xD;
&#xD;
          -  Washout period: if previous progression on ROS1-TKI: 7 days from last dose of the&#xD;
             drug. The washout period may be shortened to 2 days at investigator discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with disease progression on front-line treatment with TKI i.e. crizotinib&#xD;
             or entrectinib limited to CNS or one non-CNS site (oligo-metastasis) and eligible to a&#xD;
             local ablative treatment (surgery or stereotaxic radiotherapy).&#xD;
&#xD;
          -  Histological transformation with neuro-endocrine differentiation.&#xD;
&#xD;
          -  Spinal cord compression is excluded unless the patient demonstrates good pain control&#xD;
             attained through therapy and there is stabilization or recovery of neurological&#xD;
             function for the 4 weeks prior to study entry.&#xD;
&#xD;
          -  Patients with symptomatic and neurologically instable CNS metastases or leptomeningeal&#xD;
             metastasis (including patients that require increasing doses of steroids within one&#xD;
             week prior to Day 0 of screening phase and during the screening phase to manage CNS&#xD;
             symptoms).&#xD;
&#xD;
          -  Major surgery within 35 days of study entry. Minor surgical procedures (eg, port&#xD;
             insertion, mediastinoscopy, surgical procedure for re-sampling) are not excluded, but&#xD;
             sufficient time at investigator discretion should have passed for wound healing.&#xD;
&#xD;
          -  Radiation therapy within 2 weeks of study entry (except palliative to relieve bone&#xD;
             pain). Palliative radiation (≤15 fractions) must have been completed at least 48 hours&#xD;
             prior to study entry. Stereotactic or small field brain irradiation must have&#xD;
             completed at least 2 weeks prior to study entry. Whole brain radiation must have&#xD;
             completed at least 4 weeks prior to study entry.&#xD;
&#xD;
          -  Prior therapy with an antibody or drug specifically targeting T-cell co-stimulation or&#xD;
             immune checkpoint pathways, including, but not limited to, anti-PD-1, anti-PD-L1,&#xD;
             anti-PD-L2, anti-CD137, or anti-CTLA-4.&#xD;
&#xD;
          -  Active and clinically significant bacterial, fungal, or viral infection including&#xD;
             hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV), or&#xD;
             acquired immunodeficiency syndrome (AIDS)-related illness.&#xD;
&#xD;
          -  Clinically significant cardiovascular disease (that is, active or &lt;3 months prior to&#xD;
             enrollment): cerebral vascular accident/stroke, myocardial infarction, unstable&#xD;
             angina, congestive heart failure (New York Heart Association Classification Class ≥&#xD;
             II), second-degree or third-degree AV block (unless paced) or any AV block with PR&#xD;
             &gt;220 msec.&#xD;
&#xD;
          -  Ongoing cardiac dysrhythmias of NCI CTCAE Grade ≥2, uncontrolled atrial fibrillation&#xD;
             of any grade, bradycardia defined as &lt;50 bpm (unless patient is otherwise healthy such&#xD;
             as long-distance runners, athletic patients etc.), machine-read ECG with QTc &gt;470&#xD;
             msec, or congenital long QT syndrome.&#xD;
&#xD;
          -  Patients with predisposing characteristics for acute pancreatitis according to&#xD;
             investigator judgment (eg, uncontrolled hyperglycemia, current gallstone disease,&#xD;
             alcoholism [more than 4 drinks on any day or 14 drinks per week where 1 drink is&#xD;
             defined as the alcoholic beverage containing approximately 14 grams of pure alcohol,&#xD;
             eg, 12 fl oz/360 mL regular beer or 5 fl oz/150 mL of wine] in the last month.&#xD;
&#xD;
          -  History of bilateral or Grade 3 or 4 interstitial fibrosis or diffuse interstitial&#xD;
             lung disease. Patients with history of prior radiation pneumonitis are not excluded.&#xD;
&#xD;
          -  Other severe acute or chronic medical or psychiatric condition, including recent&#xD;
             (within the past year) or active suicidal ideation or behavior, or laboratory&#xD;
             abnormality that may increase the risk associated with study participation or&#xD;
             investigational product administration or may interfere with the interpretation of&#xD;
             study results and, in the judgment of the investigator, would make the patient&#xD;
             inappropriate for entry into this study.&#xD;
&#xD;
          -  Evidence of active malignancy (other than current NSCLC, non-melanoma skin cancer, in&#xD;
             situ cervical cancer, papillary thyroid cancer, DCIS of the breast or localized and&#xD;
             presumed cured prostate cancer) within the last 3 years.&#xD;
&#xD;
          -  Active inflammatory gastrointestinal disease, chronic diarrhea, symptomatic&#xD;
             diverticular disease or previous gastric resection or lap band.&#xD;
&#xD;
          -  Current use or anticipated need for food or drugs prohibited (see chapter 8.8.1 for&#xD;
             details).&#xD;
&#xD;
          -  Patients presenting with abnormal Left Ventricular Ejection Fraction (LVEF) by&#xD;
             echocardiogram or Multi-Gated Acquisition Scan (MUGA) according to institutional lower&#xD;
             limits.&#xD;
&#xD;
          -  Breastfeeding female patients (including patients who intend to interrupt&#xD;
             breastfeeding).&#xD;
&#xD;
          -  Liver disease characterized by: ALT or AST level &gt; 3 the upper normal limit (UNL) (≥ 5&#xD;
             x UNL for patients with liver metastases) confirmed on 2 consecutive measures OR&#xD;
             impaired excretory function (e.g.. hyperbilirubinemia) or synthetic function or other&#xD;
             conditions of decompensated liver disease e.g.: coagulopathy, Hepatic encephalopathy,&#xD;
             hypoalbuminemia, ascites and bleeding from esophageal varices OR Acute viral or&#xD;
             autoimmune or other types of hepatitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Moro-Sibilot</last_name>
    <role>Study Chair</role>
    <affiliation>Grenoble - CHU</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Duruisseaux</last_name>
    <role>Study Chair</role>
    <affiliation>Lyon - URCOT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier du Pays d'Aix</name>
      <address>
        <city>Aix-en-Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie Martinez, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BIGOT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Capucine Willemin, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annecy - CH</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorine TEMPLEMENT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antony - Hôpital privé</name>
      <address>
        <city>Antony</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanislas ROPERT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avignon - CH</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas CLOAREC, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Schneider, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - CHU</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maéva ZYSMAN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie COUSIN, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Ambroise Paré</name>
      <address>
        <city>Boulogne</city>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coraline Dumenil, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chauny - CH</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick DUMONT, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cholet - CH</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MASSON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont-Ferrand - CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick MERLE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel MOREAU</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Monnet, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon - CRLCC</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure FAVIER, dR</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MORO-SIBILOT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Molinier, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Cortot, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélie Swalduz, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Madroszyk, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Tomasini, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GRH Mulhouse Sud-Alsace</name>
      <address>
        <city>Mulhouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Wislez, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <phone>+33.1.56.01.65.31</phone>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Cadranel, pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie Gounant, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Ange MASSIANI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyon - URCOT</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Duruisseaux, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian GUISIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nouvel Hôpital Civil - Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline Mascaux, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène Doubre, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse - Pneumologie</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Rabeau, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine Carmier, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valenciennes - Clinique</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène MEYER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vandoeuvre-lès-Nancy - CHU</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurélien BRINDEL, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Villefranche-sur-Saône</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Odier, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Planchard, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ifct.fr/index.php/fr/la-recherche/item/2215-ifct-2003-albatros</url>
    <description>Description IFCT website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>November 4, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IFCT</keyword>
  <keyword>ALBATROS</keyword>
  <keyword>NSCLC</keyword>
  <keyword>ROS1-positive</keyword>
  <keyword>monotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

